The Effect Analysis of Metoprolol Sustained-release Tablets Combined with Trimetazidine in the Treatment of Coronary Heart Disease Compli-cated with Chronic Heart Failure and the Improvement of Patients'Qual-ity of Life
Objective To study the clinical effect of metoprolol sustained-release tablets and trimetazidine in patients with coronary atherosclerotic heart disease(CHD)complicated with chronic heart failure(CHF).Methods A total of 72 patients with CHD complicated with CHF admitted to Anxi County Hospital from June 2021 to June 2023 were conve-niently selected as study objects and divided into control group and observation group by random number table method,36 cases in each group.The control group was treated with metoprolol sustained-release tablets alone,and the observation group was treated with metoprolol sustained-release tablets combined with trimetazidine.The efficacy,cardiac function and quality of life of the two groups were compared.Results The total effective rate of the observation group(94.44%)was higher than that of the control group(77.78%),and the difference was statistically significant(χ2=4.180,P=0.040).After treatment,the cardiac function indexes of the observation group was better than those of the control group,and the difference was statistically significant(P＜0.05).After treatment,the score of the Quality of Life Scale in the observation group was higher than those in the control group,and the difference was statistically signifi-cant(P＜0.05).Conclusion The combination of metoprolol sustained-release tablets and trimetazidine can improve the efficacy of CHD patients with CHF,better restore their cardiac function and improve their quality of life.
Coronary heart diseaseChronic heart failureMetoprolol sustained release tabletsTrimetazidineQuality of Life
NETL
NSTL
万方数据
